Evidence map›Paper›PMID 38839335›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED).

Nobumi Suzuki, Nariaki Odawara, Gota Fujisawa, Rei Ishibashi, Masahiro Hata, Yukiko Oya, Kenji Tamada, Takeshi Hayashi, Sohei Abe, Yu Miyakawa and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nobumi SuzukiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Nariaki OdawaraDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Gota FujisawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Rei IshibashiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Masahiro HataDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Yukiko OyaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Kenji TamadaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Takeshi HayashiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Sohei AbeDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Yu MiyakawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Yoku HayakawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Aya Shinozaki-UshikuDepartment of Pathology, The University of Tokyo Hospital, Japan.
Tetsuo UshikuDepartment of Pathology, The University of Tokyo Hospital, Japan.
Narikazu BokuDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.

Indexed as

AdenocarcinomaCamptothecinErb-b2 Receptor Tyrosine KinasesLung Diseases, InterstitialStomach NeoplasmsTrastuzumabAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImmunoconjugatesLung NeoplasmsTaxoidsTreatment OutcomeCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTaxoidsTrastuzumabtrastuzumab deruxtecangastric adenocarcinoma with enteroblastic differentiationgastric cancerHER2trastuzumab deruxtecan

Identifiers

PMID38839335
PMCPMC11781934

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.